Pharmaceutical Technology

JANUARY 4, 2023

Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies.

Licensing 130

Licensing Licensing Sales Clinical Development 130

Drug Discovery World

APRIL 17, 2024

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. Arvinas will receive an upfront payment in the aggregate amount of $150 million.

Protein 52

Protein Licensing Licensing Sales 52

The Pharma Data

JANUARY 12, 2021

13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. , www.evoqtherapeutics.com.

Licensing 52

Licensing Licensing Sales Clinical Development 52

The Pharma Data

AUGUST 5, 2020

AstraZeneca has signed a licensing deal with UK-based biotech company Redx Pharma for its fibrotic disease candidate RXC006. Redx is also eligible to receive up to $360m in additional payments, dependent on development, regulatory and commercial milestones, as well as tiered royalties on any future sales.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors.

Licensing 72

Licensing Licensing Trials Clinical Trials 72

Pharmaceutical Technology

AUGUST 25, 2022

The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial. The company plans to resubmit a Biologics License Application (BLA) for Roctavian by the end of next month.

Gene Therapy 264

Gene Therapy Gene Clinical Trials Clinical Trials 264

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. Why has there been so little progress in medicine? 1 Can this really be regarded as a success? Why has it been so unproductive?

Medicine 59

Medicine Genome Genomics Drugs 59

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

Pharmaceutical Technology

OCTOBER 11, 2022

Swiss biotech company Stalicla has signed a licensing deal with Evgen Pharma for the latter’s lead asset, SFX-01, in neurodevelopmental disorders and schizophrenia. It is claimed to be the only grade of sulforaphane which is suitable for clinical research and will eventually be approved as a medicine.

Clinical Development 147

Clinical Development Licensing Licensing Clinical Research 147

Pharmaceutical Technology

MARCH 1, 2023

Orvacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Pharmacy 100

Pharmacy Production Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JANUARY 2, 2023

Danicamtiv is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. Danicamtiv overview Danicamtiv (MYK-491, DCM-1) is under development for the treatment of dilated cardiomyopathy (DCM), atrial fibrillation and systolic heart failure.

Drugs 100

Drugs Pharmacy Production Development 100

XTalks

MARCH 1, 2021

The study is part of a broad development plan to assess the durability of the immunogenic responses elicited by its vaccine and the emergence of new SARS-CoV-2 variants. Our proactive clinical development strategy aims to create the foundation today, that will enable us to address the challenges of tomorrow.

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

Drug Discovery World

JANUARY 10, 2024

The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications.

Antibody 52

Antibody Licensing Licensing Medicine 52

The Pharma Data

MARCH 16, 2021

Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. The Lieber Institute for Brain Development. Boehringer Ingelheim.

Development 52

Development Contract Manufacturing Licensing Licensing 52

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth. of Perspective’s shares for up to $33 million.

Drugs 59

Drugs Licensing Licensing Protein 59

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Trials 52

Trials Clinical Trials Clinical Trials Licensing 52

Drug Discovery World

JUNE 1, 2023

According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.

Clinical Trials 52

Clinical Trials Clinical Trials Development Trials 52

pharmaphorum

MAY 4, 2022

In testing new treatments, what is promising in animal models may not transfer particularly well to humans, which helps to explain why there is a 90% failure rate during clinical development. Quris has taken its technology and used it to develop its own drug candidate pipeline. Nascent technology.

Drugs 143

Drugs Licensing Licensing Pharma Companies 143

Drug Discovery World

SEPTEMBER 14, 2023

Excluding contributions from Comirnaty and Paxlovid, company revenues grew $537 million, or 5%, operationally. AstraZeneca saw total revenue reach $22,295m, up 4% despite a decline of $2,181m from Covid-19 medicines. Excluding Covid-19 medicines, total revenue increased 16% and product sales increased 15%. Specialty care grew 11.8%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S.

Licensing 52

Licensing Licensing Vaccination Vaccine 52

The Pharma Data

NOVEMBER 30, 2020

The lead candidate, HTL0022562, has advanced through preclinical development demonstrating promising and differentiated properties for further investigation in human trials. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.”

Licensing 40

Licensing Licensing Production Development 40

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. The post Astellas teams up with UK biotech Mogrify on hearing loss project appeared first on.

In-Vivo 102

In-Vivo Bioinformatics Genetics Licensing 102

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. “Adding Acuitas’ clinically-validated and scalable LNP technology to our genomic medicine toolbox is another important step to advance our leadership in the field of cell and gene therapies.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

DECEMBER 21, 2021

South San Francisco-based Amunix specialises in T-cell engager and cytokine-based treatments for solid tumours, and is planning to advance its lead programme AMX-818 – a cell-based therapy which targets HER2-expressing cancers – into the clinic next year. Sanofi’s other acquisitions this year were the $3.2 billion upfront.

Licensing 122

Licensing Licensing Protein Clinical Development 122

Camargo

AUGUST 11, 2021

As regulatory requirements become increasingly harmonized across the globe, the development and marketing of pharmaceutical products worldwide are also becoming more streamlined. In scientific advice meetings, the goal is to confirm the adequacy of existing information to support the next steps in a development program.

Production 230

Production Packaging Packaging Marketing 230

Drug Discovery World

JUNE 5, 2023

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has acquired Theragnostics, a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.

FDA Approval 52

FDA Approval DNA Production Licensing 52

Drug Discovery World

DECEMBER 20, 2022

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). . The therapy was also recently approved by the FDA for patients in the US. . World’s most expensive drug.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact. Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact.

Licensing 40

Licensing Licensing Clinical Development Medicine 40

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. Terms of Termination. GALACTIC-HF : Results and Next Steps.

Development 52

Development Clinical Trials Clinical Trials Trials 52

The Pharma Data

APRIL 27, 2022

We plan to discuss these data with health authorities, and we will continue to expand our tislelizumab clinical development program in pursuit of novel, synergistic combinations with the ultimate goal of extending survival for more patients.”. About Novartis Novartis is reimagining medicine to improve and extend people’s lives.

Medicine 52

Medicine Clinical Development Gene Therapy Development 52

The Pharma Data

DECEMBER 12, 2020

We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients.” ” Ludwig Hantson , Ph.D., Strategic rationale.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. Experienced executive development team from Gilead Sciences. ” Vera has executive and clinical development teams with deep experience in drug development and commercialization from Gilead Sciences.

Development 52

Development Life Science Protein Clinical Development 52

Drug Discovery World

AUGUST 12, 2022

VLA15 is the only Lyme disease vaccine candidate currently in clinical development. If the Phase III trial is successful, Pfizer aims to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025. .

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S. Berk, MD, to its Board of Directors.

Clinical Development 40

Clinical Development Development Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. and Roche will develop, manufacture and distribute it outside of the U.S.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

MARCH 11, 2022

AbbVie’s longstanding alliance with Hungarian drugmaker Gedeon Richter has already given it one blockbuster medicine – Vraylar for schizophrenia and bipolar disorder – and the two partners have just decided to extend their working relationship. ” The deal is expected to close in the second quarter of 2022.

Sales 52

Sales Licensing Licensing Development 52